ALKS - アルケルメス (Alkermes plc) アルケルメス

 ALKSのチャート


 ALKSの企業情報

symbol ALKS
会社名 Alkermes plc (アルケルメス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルケルメス(Alkermes plc.)(Alkermes Inc.)は統合されたバイオテクノロジー企業。同社は一般的な慢性疾患の治療のための医薬品の開発、製造と商品化に従事している。同社はアルコール依存症の治療薬「VIVITROL」の開発・製造・商品化、及び統合失調症と双極I型障害の治療薬「RISPERDAL CONSTA」の製造を行っている。同社の薬品パイプラインは中枢神経系(CNS)疾患、報酬障害、中毒、糖尿病と自己免疫疾患などの一般的な慢性疾患の治療のための徐放性注射剤と経口製品を含む。同社はマサチューセッツ州に1カ所の研究施設、オハイオ州に1カ所の商業生産施設を有している。平成23年9月、同社はアイルランドで事業活動を開始した。平成23年9月16日、同社はElan Corporation plc (Elan)の製剤と薬品製造事業ユニットであるエラン医薬品テクノロジーズ(EDT)と合併した。  アルケルメスはアイルランドのバイオ医薬品会社。依存症、統合失調症、うつ病など中枢神経障害の治療用製品の開発と商業化に従事。製品には統合失調症治療薬「リスパダ―ル・コンスタ」、多発性硬化症治療薬「アムピラ」、2型糖尿病治療薬徐放性剤「ビデュリオン」、アルコ―ル依存症治療薬「ビビトロル」などがある。   
本社所在地 Connaught House 1 Burlington Road Dublin 02451 IRL
代表者氏名 Richard F. Pops リチャードF.ポップス
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +353 1-772-8000
設立年月日 31959
市場名 NASDAQ National Market System
ipoyear 1991年
従業員数 2000人
url www.alkermes.com
nasdaq_url https://www.nasdaq.com/symbol/alks
adr_tso
EBITDA EBITDA(百万ドル) 7.23400
終値(lastsale) 44.45
時価総額(marketcap) 6903759662.1
時価総額 時価総額(百万ドル) 6709.616
売上高 売上高(百万ドル) 122.547
企業価値(EV) 企業価値(EV)(百万ドル) 6556.5
当期純利益 当期純利益(百万ドル) -119.76600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alkermes Plc revenues increased 29% to $529.8M. Net loss decreased 15% to $95.2M. Revenues reflect Product sales net increase of 22% to $201.6M Research and development revenue increase from $1.5M to $37.1M. Lower net loss reflects Interest Income increase of 60% to $3.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.73 to -$0.61.

 ALKSのテクニカル分析


 ALKSのニュース

   H.C. Wainwright Stick to Their Hold Rating for Alkermes By Investing.com  2021/04/08 10:15:07 Investing.com
H.C. Wainwright Stick to Their Hold Rating for Alkermes
   Mizuho Securities Stick to Their Buy Rating for Alkermes By Investing.com  2021/04/01 01:25:01 Investing.com
Mizuho Securities Stick to Their Buy Rating for Alkermes
   Global Psychedelic Drugs Market Report 2020 Featuring Emmes Company, Klarisana, AstraZeneca, F. Hoffmann-La Roche, Dr. Reddy's Labs, Takeda, Pfizer, Mylan, Merck & Co., Alkermes & Allergan  2021/03/22 17:00:00 PR Newswire
DUBLIN, March 22, 2021 /PRNewswire/ -- The "Psychedelic Drugs Market, By Drugs (LSD, Ecstasy, Phencyclidine, GHB, Ketamine, Ayahuasca, Psilocybin), Route of Administration (Oral, Injectable, Inhalation), Distribution Channel, End-Users, Application and Geography - Global Forecast to 2026"…
   Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma  2021/03/11 12:00:00 PR Newswire
DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered interleukin-2 (IL-2) variant immunotherapy, has been granted orphan drug designation for…
   Alkermes to Hold Virtual Investor Day  2021/03/04 13:00:00 PR Newswire
DUBLIN, March 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will hold a virtual Investor Day on Thursday, March 25, 2021, beginning at 9:00 a.m. ET (1:00 p.m. GMT). During the event, members of Alkermes' senior management and research and development team…
   Global Psychedelic Drugs Market Report 2020 Featuring Emmes Company, Klarisana, AstraZeneca, F. Hoffmann-La Roche, Dr. Reddy's Labs, Takeda, Pfizer, Mylan, Merck & Co., Alkermes & Allergan  2021/03/22 17:00:00 PR Newswire
DUBLIN, March 22, 2021 /PRNewswire/ -- The "Psychedelic Drugs Market, By Drugs (LSD, Ecstasy, Phencyclidine, GHB, Ketamine, Ayahuasca, Psilocybin), Route of Administration (Oral, Injectable, Inhalation), Distribution Channel, End-Users, Application and Geography - Global Forecast to 2026"…
   Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma  2021/03/11 12:00:00 PR Newswire
DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered interleukin-2 (IL-2) variant immunotherapy, has been granted orphan drug designation for…
   Alkermes to Hold Virtual Investor Day  2021/03/04 13:00:00 PR Newswire
DUBLIN, March 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will hold a virtual Investor Day on Thursday, March 25, 2021, beginning at 9:00 a.m. ET (1:00 p.m. GMT). During the event, members of Alkermes' senior management and research and development team…
   $ 6.54 Billion Growth in Military Robots Market During 2021-2025 | Featuring Alkermes Plc and Emergent BioSolutions Inc. among others | Technavio  2021/02/24 15:00:00 PR Newswire
NEW YORK, Feb. 24, 2021 /PRNewswire/ -- Amid the COVID-19 pandemic, the global military robots market registered a YOY growth of 5.92% in 2020 and the market is estimated to expand at a CAGR of about 7% during the forecast period. The report offers a detailed analysis of the impact of the…
   Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference  2021/02/18 21:00:00 PR Newswire
DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 24, 2021 at 9:20 a.m. ET (2:20 p.m. GMT). The presentation may be accessed under…
   Safer mobility for all: Countries agree on regulations for automated driving  2020/06/29 19:19:20 TheSouthAfrican
The binding rules on Automated Lane Keeping Systems (ALKS) will come into force in January 2021.
   Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program  2020/06/29 11:00:00 PR Newswire
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program…
   Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities  2020/06/24 11:00:00 PR Newswire
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that 10 nonprofit organizations have been awarded grants from the company's COVID-19 Relief Fund, a…
   New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II  2020/06/22 13:01:00 PR Newswire
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to…
   The first step in the AI journey is often conquering data silos. Here's how a $1.17 billion drug maker is using a 25-person team to create a unified data platform.  2020/06/10 16:49:36 Business Insider
Cataloging the data stored internally across enterprises is a major focus for companies right now. Some are trying to adopt new, AI-based applications, while others are trying to comply with new data privacy regulations around the globe. The drug manufacturer Alkermes launched a 25-person group to begin examining how data is being used in the organization right now and where the potential areas of collaboration are. "It's not really because of AI and machine learning. It's because we realize that more and more people are trying to unlock the data," CIO Tom Harvey told Business Insider. Click here for more BI Prime stories. Sign up here to receive updates on all things Innovation Inc . BOSTON, MASSACHUSETTS — Companies are rushing to catalogue the data they have stored internally. It's such a hot market that startups that assist organizations with it are raising hundreds of millions of dollars in new funding despite the coronavirus pandemic cooling investment . There's many reasons why organizations are eager to organize their stored information.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルケルメス ALKS Alkermes plc)

 twitter  (公式ツイッターやCEOツイッターなど)